Results 11 to 20 of about 313,407 (265)

Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Journal of Hematology & Oncology, 2023
There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO).
Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Mohamed Houhou, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty, Norbert-Claude Gorin   +15 more
doaj   +1 more source

Acute Leukemia in Women

Women's Health, 2010
The treatment and survival outcome of acute leukemia in women is generally similar to that of men. However, acute leukemia in women poses additional challenges in clinical practice. In addition to important precautions during therapy, such as prevention of abnormal uterine bleeding in premenopausal women and therapy during pregnancy, women who are ...
LO COCO, FRANCESCO, Fouad, TM, Ramadan, SM   +2 more
openaire   +4 more sources

Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia

Haematologica, 2023
Pediatric acute myeloid leukemia (AML) is a highly heterogeneous disease making standardized measurable residual disease (MRD) assessment challenging. Currently, patient-specific DNA-based assays are only rarely applied for MRD assessment in pediatric ...
Margarita Maurer-Granofszky, Stefan Kohrer, Susanna Fischer, Angela Schumich, Karin Nebral, Patrizia Larghero, Claus Meyer, Astrid Mecklenbrauker, Nora Muhlegger, Rolf Marschalek, Oskar A. Haas, Renate Panzer-Grumayer, Michael N. Dworzak   +12 more
doaj   +1 more source

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT

Haematologica, 2020
Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia (AML) is a common high-risk feature that is referred to allogeneic stem cell transplantation.
Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Edouard Forcade, Arnold Ganser, Liisa Volin, Mauricette Michallet, Didier Blaise, Ibrahim Yakoub-Agha, Johan Maertens, Carlos Richard Espiga, Jan Cornelissen, Jürgen Finke, Mohamad Mohty, Jordi Esteve, Arnon Nagler   +15 more
doaj   +1 more source

Acute Megakaryocytic Leukemia

Cold Spring Harbor Perspectives in Medicine, 2019
Acute megakaryoblastic leukemia (AMKL) is a rare malignancy affecting megakaryocytes, platelet-producing cells that reside in the bone marrow. Children with Down syndrome (DS) are particularly prone to developing the disease and have a different age of onset, distinct genetic mutations, and better prognosis as compared with individuals without DS who ...
Maureen, McNulty, John D, Crispino
openaire   +3 more sources

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Journal of Hematology & Oncology, 2017
Background Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative ...
Xavier Poiré, Myriam Labopin, Johan Maertens, Ibrahim Yakoub-Agha, Didier Blaise, Norbert Ifrah, Gérard Socié, Tobias Gedde-Dhal, Nicolaas Schaap, Jan J. Cornelissen, Stéphane Vigouroux, Jaime Sanz, Lucienne Michaux, Jordi Esteve, Mohamad Mohty, Arnon Nagler   +15 more
doaj   +1 more source

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Haematologica, 2018
Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of FLT3 (FLT3-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation.
Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Jakob Passweg, Charles Craddock, Didier Blaise, Jan J. Cornelissen, Liisa Volin, Nigel H. Russell, Gérard Socié, Mauricette Michallet, Nathalie Fegueux, Patrice Chevallier, Arne Brecht, Mathilde Hunault-Berger, Mohamad Mohty, Jordi Esteve, Arnon Nagler   +17 more
doaj   +1 more source

Genomic Diversity and Clinical Variability in Pediatric Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Series

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare pediatric CD30‐positive T‐cell lymphoproliferative disorder with an excellent prognosis, but its genomic drivers are poorly defined. We report three children with skin‐limited disease demonstrating striking molecular heterogeneity, including NPM::ALK, NUP214::FRK, and a novel ...
Shoshana Greenberger, Efrat Bar‐Ilan, Victoria Marcu, Evgeny Grishin, Rinat Yacobi, Aviv Barzilai, Hana Golan, Assaf Arie Barg   +7 more
wiley   +1 more source

NUP214 in Acute Myeloid Leukemia

Cells
Nucleoporin 214 (NUP214) is a component of the nucleopore molecular complex, but in addition to this role in nucleocytoplasmic transport it is also involved in the regulation of gene transcription/translation, intracellular signaling, cell cycle ...
Øystein Bruserud, Håkon Reikvam
doaj   +1 more source

Prevalence of 21 Physician‐Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier, Brittany Grantham, Camilla Grud Nielsen, Louise Lundgren, Liv Andrés‐Jensen, Kjeld Schmiegelow, Chris Selman, Gareth Ball, Elyse Passmore, David A. Elliott, Rachel Conyers   +10 more
wiley   +1 more source